Three out of four is not bad for Abbvie’s Jak

Snippets

Two thirds of upadacitinib’s $2.2bn forecast 2024 sales are to come from its use in rheumatoid arthritis, according to sellside data compiled by EvaluatePharma. But the $700m forecast for the Abbvie asset’s second indication, ulcerative colitis, is not to be sneezed at. The positive data from the phase IIb part of the U-Achieve study – the first for the project in this condition – are, therefore, important for Abbvie. U-Achieve tested four doses of the Jak1 inhibitor in adults with moderately to severely active UC. After eight weeks, significantly more patients given the three highest doses of upadacitinib achieved clinical remission per the Adapted Mayo Score – a measure of symptom severity – compared with placebo. The lowest dose was not significantly better than placebo on this endpoint. Upadacitinib will now enter the phase III part of U-Achieve, presumably with the higher doses being pursued since the drug’s safety profile was pretty clean – important to note after previous safety concerns with Jaks. Full data from the study, as well as the two other phase III trials that make up upadacitinib’s pivotal programme in UC, are expected in 2021 or 2022.

U-Achieve efficacy results at week 8
  Upadacitinib  
  7.5 mg 15 mg 30 mg 45 mg Placebo
No of patients 47 49 52 56 46
Clinical remission (per Adapted Mayo Score) 9% 14%* 14%* 20%** 0%
Endoscopic improvement 15%* 31%*** 27%*** 36%*** 2%
Clinical remission (per Full Mayo Score) 9% 10%* 12%* 20%** 0%
Clinical response (per Adapted Mayo Score) 30* 45%*** 44%*** 50%*** 13%
Serious adverse events  0% 4% 6% 5% 11%
Serious infections  0% 2% 0% 4% 4%
*p<0.05, **p<0.01, ***p<0.001. Source: Adapted from company communication.

 

Sales by indication for AbbVie’s upadacitinib 
    WW sales ($m)
Indication Status 2018 2019 2020 2021 2022 2023 2024
Arthritis, rheumatoid Phase III - 59 273 660 1,008 1,254 1,487
Ulcerative colitis Phase III - - - - 169 432 697
Total   - 59 273 660 1,177 1,686 2,184
Source: EvaluatePharma.

 

Share This Article